ClinicalTrials.gg
CompletedNCT00192036Updated Dec 9, 2010Results posted

Multicenter Phase 2 Trial Evaluating Cisplatin-Gemcitabine With Concomitant Thoracic Radiotherapy for Treatment of Inoperable Stage III Non Small Cell Lung Cancer

A Phase 2 interventional study of gemcitabine and cisplatin in Non Small Cell Lung Cancer, sponsored by Eli Lilly and Company. Completed at 8 sites in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-12-09.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
49
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 169 studies testing gemcitabine in Carcinoma, Non-Small-Cell Lung — 4 open to participants now, 5 under way, none of them phase 3. Gemcitabine · Carcinoma, Non-Small-Cell Lung.

Enrollment
83rd of 152
49 · median 53
Started
2004
with 15 others
Phase 2
109 of 169
4 open now
Registered
49th of 169
by date
Lead sponsor
21 of 169
Eli Lilly and Company

Among the 169 studies testing gemcitabine in Carcinoma, Non-Small-Cell Lung, this one is the 83rd largest by enrollment of the 152 interventional ones that give a count, is one of 16 that started in 2004, is one of 109 in phase 2, and was the 49th registered.

Carcinoma, Non-Small-Cell Lung

7,635 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,840 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

4 of the 169 studies testing gemcitabine in Carcinoma, Non-Small-Cell Lung are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About gemcitabine

Gemcitabine: first FDA approval 1996 (GEMZAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 989 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 169 studies testing gemcitabine in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the response rate of patients with non small lung cancer to gemcitabine in combination with radiotherapy. The tolerability and safety of this combination will also be evaluated.

03

Conditions studied

  • Non Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Inoperable non small cell lung cancer Stage III
  • Adequate hematological parameters
  • Adequate Lung function reserve

Exclusion criteria

Exclusion Criteria:

  • Previous chemotherapy and thoracic radiation for non small cell lung cancer
  • Presence of distant
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
49 participants (actual)

Study arms

  • Experimental
    Gemcitabine + Cisplatin

    Gemcitabine: 1250 mg/m2, intravenous (IV), day 1 and day 8 every 21 days x 3 cycles (1-3) then 300 mg/m2 x 2 cycles (4-5). Cisplatin: 80 mg/m2, IV, every 21 days x 5 cycles. Radiation: 63 Gray (Gy) in 35 treatments over 7 weeks concurrent with chemotherapy cycles 4 and 5.

    Drug: gemcitabine · Drug: cisplatin · Radiation: radiation

Interventions

  • 1250 mg/m2, intravenous (IV), day 1 and day 8 every 21 days x 3 cycles (1-3) then 300 mg/m2 x 2 cycles (4-5)

    Also known as: LY188011, Gemzar

  • 80 mg/m2, IV, every 21 days x 5 cycles

  • Radiationradiation

    63 Gray (Gy) in 35 treatments over 7 weeks concurrent with chemotherapy cycles 4 and 5

06

What researchers measure

Primary outcomes

  1. Tumor Response at End of Treatment

    Response recorded at the first follow-up visit using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions; Partial Response=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that do not meet above criteria.

    Time frame: baseline to first follow-up visit (up to 8 weeks after end of chemo-radiation)

Secondary outcomes

  1. Time to Progressive Disease

    Time to progressive disease is the time from the date of enrollment to the first date of documented disease progression. Patients who have not had disease progression will be censored at the date of the last follow-up visit. Patients dying because of reasons other than tumor progression are not included.

    Time frame: Preliminary: baseline to measured progressive disease (up to 3.5 years); Final: baseline to measured progressive disease (up to 5 years);

  2. Overall Survival

    Overall survival is the duration from enrollment to death. For patients who are alive, overall survival is censored at the last contact.

    Time frame: Preliminary: baseline to date of death from any cause (up to 3.5 years); Final: baseline to date of death from any cause (up to 5 years)

  3. Safety of Induction Chemotherapy

    A grading (severity) scale is provided for each adverse event term. Toxicities were graded according to the National Cancer Institute Common Toxicity Criteria (NCI-CTC) Version 2.0 grading scales. Grades range from 0 (none) to 5 (death). Number of participants with clinically significant Grade 3 and Grade 4 toxicities occurring during induction chemotherapy are reported. Grade 3 events are severe and Grade 4 events are life-threatening.

    Time frame: every cycle (21 days) for 3 cycles (up to 10 weeks)

  4. Safety of Chemo-radiotherapy

    A grading (severity) scale is provided for each adverse event term. Toxicities were graded according to NCI-CTC Version 2.0 grading scales. For specific radiation events, Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer late radiation toxicity scale was used. Grades range from 0 (none) to 5 (death). Number of participants with clinically significant acute Grade 3 and Grade 4 toxicities (worst severity) occurring during chemo-radiation and up to 49 days (8 weeks) after are reported. Grade 3 events are severe and Grade 4 events are life-threatening.

    Time frame: Cycles 4 and 5 up to 8 weeks after the end of chemo-radiotherapy

07

Results

Posted Mar 25, 2009
Limitations and caveats
Enrollment was stopped early due to difficulties with patient recruitment. Given the number of missing/unknown tumor assessments, care should be taken when interpreting the primary outcome measure. An identified error was corrected in the results.

Participant flow

Participant flow — Overall Study
MilestoneGemcitabine + Cisplatin
Started49
Completed28
Not completed21
Withdrew: Protocol violation3
Withdrew: Adverse event6
Withdrew: Patient/physician perception1
Withdrew: Objective tumor progression4
Withdrew: Clinical disease progression1
Withdrew: Death1
Withdrew: Unknown or not specified5

Outcome measures

PrimaryTumor Response at End of Treatment

Response recorded at the first follow-up visit using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions; Partial Response=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that do not meet above criteria.

Time frame:
baseline to first follow-up visit (up to 8 weeks after end of chemo-radiation)
Reported as:
Number · participants
Tumor Response at End of Treatment
participantsGemcitabine + Cisplatin
Complete Response1
Partial Response18
Stable Disease3
Progressive Disease1
Unknown22
Missing4
SecondaryTime to Progressive Disease

Time to progressive disease is the time from the date of enrollment to the first date of documented disease progression. Patients who have not had disease progression will be censored at the date of the last follow-up visit. Patients dying because of reasons other than tumor progression are not included.

Time frame:
Preliminary: baseline to measured progressive disease (up to 3.5 years); Final: baseline to measured progressive disease (up to 5 years);
Reported as:
Median · months
Time to Progressive Disease
monthsGemcitabine + Cisplatin
Preliminary10.9 (0.9 to 39.2)
Final11.4 (9.4 to 12.9)
SecondaryOverall Survival

Overall survival is the duration from enrollment to death. For patients who are alive, overall survival is censored at the last contact.

Time frame:
Preliminary: baseline to date of death from any cause (up to 3.5 years); Final: baseline to date of death from any cause (up to 5 years)
Reported as:
Median · months
Overall Survival
monthsGemcitabine + Cisplatin
Preliminary27.9 (0.9 to 39.2)
Final21.8 (17.5 to 26.0)
SecondarySafety of Induction Chemotherapy

A grading (severity) scale is provided for each adverse event term. Toxicities were graded according to the National Cancer Institute Common Toxicity Criteria (NCI-CTC) Version 2.0 grading scales. Grades range from 0 (none) to 5 (death). Number of participants with clinically significant Grade 3 and Grade 4 toxicities occurring during induction chemotherapy are reported. Grade 3 events are severe and Grade 4 events are life-threatening.

Time frame:
every cycle (21 days) for 3 cycles (up to 10 weeks)
Reported as:
Number · participants
Safety of Induction Chemotherapy
participantsGemcitabine + Cisplatin
Neutropenia - Grade 39
Neutropenia - Grade 48
Thrombocytopenia - Grade 34
Thrombocytopenia - Grade 41
SecondarySafety of Chemo-radiotherapy

A grading (severity) scale is provided for each adverse event term. Toxicities were graded according to NCI-CTC Version 2.0 grading scales. For specific radiation events, Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer late radiation toxicity scale was used. Grades range from 0 (none) to 5 (death). Number of participants with clinically significant acute Grade 3 and Grade 4 toxicities (worst severity) occurring during chemo-radiation and up to 49 days (8 weeks) after are reported. Grade 3 events are severe and Grade 4 events are life-threatening.

Time frame:
Cycles 4 and 5 up to 8 weeks after the end of chemo-radiotherapy
Reported as:
Number · participants
Safety of Chemo-radiotherapy
participantsGemcitabine + Cisplatin
Neutropenia - Grade 36
Neutropenia - Grade 42
Thrombocytopenia - Grade 37
Thrombocytopenia - Grade 41
Radiation Esophagitis - Grade 34
Radiation Esophagitis - Grade 40
Radiation Pneumonitis - Grade 31
Radiation Pneumonitis - Grade 40

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Gemcitabine + Cisplatin—13/49 (26.5%)48/49 (98%)
Most frequent serious events
Showing 10 of 22
Most frequent serious events
EventGemcitabine + Cisplatin
Radiation oesophagitisInjury, poisoning and procedural complications4/49
Febrile neutropeniaBlood and lymphatic system disorders2/49
NeutropeniaBlood and lymphatic system disorders2/49
VomitingGastrointestinal disorders2/49
Radiation pneumonitisInjury, poisoning and procedural complications2/49
AnorexiaMetabolism and nutrition disorders2/49
LeukopeniaBlood and lymphatic system disorders1/49
ThrombocytopeniaBlood and lymphatic system disorders1/49
Atrial fibrillationCardiac disorders1/49
DysphagiaGastrointestinal disorders1/49
Most frequent other events
Showing 10 of 28
Most frequent other events
EventGemcitabine + Cisplatin
NauseaGastrointestinal disorders34/49
AnaemiaBlood and lymphatic system disorders32/49
NeutropeniaBlood and lymphatic system disorders29/49
VomitingGastrointestinal disorders28/49
LeukopeniaBlood and lymphatic system disorders22/49
LymphopeniaBlood and lymphatic system disorders22/49
ThrombocytopeniaBlood and lymphatic system disorders22/49
FatigueGeneral disorders21/49
ConstipationGastrointestinal disorders19/49
AnorexiaMetabolism and nutrition disorders16/49

Baseline characteristics

Age Continuous
Age Continuous(years)Gemcitabine + Cisplatin
Mean63.1 ± 8.41
Sex: Female, Male
Sex: Female, Male(Participants)Gemcitabine + Cisplatin
Female13
Male36
Region of Enrollment
Region of Enrollment(participants)Gemcitabine + Cisplatin
Belgium49
Basis for Pathological Diagnosis
Basis for Pathological Diagnosis(participants)Gemcitabine + Cisplatin
Histopathological39
Cytological10
Disease Stage
Disease Stage(participants)Gemcitabine + Cisplatin
Stage IIIA14
Stage IIIB35
Karnofsky Performance Status Scale
Karnofsky Performance Status Scale(participants)Gemcitabine + Cisplatin
80 - Activity with effort; some signs of disease9
90 - Normal activity; minor signs of disease24
100 - Normal no complaints; no evidence of disease16
Pathological Diagnosis
Pathological Diagnosis(participants)Gemcitabine + Cisplatin
Adenocarcinoma of Lung18
Large Cell7
Other Pathological Diagnosis2
Squamous Cell22
Time Since Diagnosis
Time Since Diagnosis(months)Gemcitabine + Cisplatin
Mean0.5 ± 0.25
08

Study locations

8 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Aalst, 9300, Belgium
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Charleroi, 6000, Belgium
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Gilly, 6060, Belgium
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Haine-St.- Paul, 7100, Belgium
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Herentals, 2200, Belgium
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Mechelen, 2800, Belgium
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ottignies, 1340, Belgium
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Turnhout, 2300, Belgium
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2004, a primary completion of Jan 2008 and a completion of Nov 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2009, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2005
First posted
Sep 19, 2005
Start
Aug 2004
Primary completionActual
Jan 2008
CompletionActual
Nov 2009
Results first posted
Mar 25, 2009
Last update
Dec 9, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 9, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00192036
First posted
Sep 19, 2005
Start date
Aug 2004
Primary completion
Jan 2008
Completion
Nov 2009
Results posted
Mar 25, 2009
Last update
Dec 9, 2010

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Gemcitabine · Cisplatin

Start the discussion